Wordt geladen...

Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report

RATIONALE: Although most of non-small cell lung cancer (NSCLC) patients with ROS1-fusions respond to crizotinb, acquired resistance eventually develop. The next-generations of ROS1 inhibitors have made some achievements, but the effects of immunotherapy have not been explored. PATIENT CONCERNS: A 44...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Medicine (Baltimore)
Hoofdauteurs: Yang, Tao, Xu, Rui, Yan, Bing, Li, Fang, Liu, Hui
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wolters Kluwer Health 2018
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6314749/
https://ncbi.nlm.nih.gov/pubmed/30593165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013797
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!